Literature DB >> 8784068

Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors?

C Dotzenrath1, B T Teh, F Farnebo, K Cupisti, A Svensson, A Toell, P Goretzki, C Larsson.   

Abstract

Allelic loss of the retinoblastoma tumor suppressor gene has recently been shown to be highly specific for parathyroid carcinoma. It has been proposed that this genetic abnormality may have diagnostic and prognostic implications for parathyroid carcinoma, but to date no further studies are available to substantiate these findings. In the present study, three cases of atypical recurrent hyperparathyroidism were examined: a patient with parathyroid carcinoma and an autotransplanted adenoma that progressed into carcinoma, a patient with recurrent juvenile hyperparathyroidism, and a patient with severe recurrent secondary hyperparathyroid disease due to rapidly growing autotransplant. Six pairs each of sporadic parathyroid adenoma and secondary parathyroid disease were also studied for comparison. Allelic losses of RB and D13S71 at 13q14 was found in the parathyroid carcinoma and the corresponding autotransplant that had previously been considered benign tissue and in the case of recurrent juvenile hyperparathyroidism, but not in any of the other tumors. Our findings support the findings of the previous study that RB or 13q loss is specific for parathyroid tumors with increased aggressiveness and might be of clinical significance.

Entities:  

Mesh:

Year:  1996        PMID: 8784068     DOI: 10.1210/jcem.81.9.8784068

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Patterns of chromosomal imbalances in parathyroid carcinomas.

Authors:  S Kytölä; F Farnebo; T Obara; J Isola; L Grimelius; L O Farnebo; K Sandelin; C Larsson
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  Immunohistochemistry in Diagnostic Parathyroid Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

3.  Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.

Authors:  S Hemmer; V M Wasenius; C Haglund; Y Zhu; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 4.  Menin and bone metabolism.

Authors:  Hiroshi Kaji
Journal:  J Bone Miner Metab       Date:  2012-04-28       Impact factor: 2.626

Review 5.  Molecular mechanisms of primary hyperparathyroidism.

Authors:  G N Hendy
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

6.  Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.

Authors:  D Scarpelli; L D'Aloiso; F Arturi; A Scillitani; I Presta; M Bisceglia; C Cristofaro; D Russo; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 7.  Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; John A Olson
Journal:  Oncologist       Date:  2010-01-05

8.  HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.

Authors:  V M Howell; C J Haven; K Kahnoski; S K Khoo; D Petillo; J Chen; G J Fleuren; B G Robinson; L W Delbridge; J Philips; A E Nelson; U Krause; K Hammje; H Dralle; C Hoang-Vu; O Gimm; D J Marsh; H Morreau; B T Teh
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

Review 9.  Parathyroid carcinoma.

Authors:  Claudio Marcocci; Filomena Cetani; Mishaela R Rubin; Shonni J Silverberg; Aldo Pinchera; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

Review 10.  Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

Authors:  Luís Cardoso; Mark Stevenson; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2017-09-25       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.